As of Jan 17, 2025, Pfizer Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $125.4. This suggests it may be undervalued by 376.8% compared to its current price of around $26.3, using a WACC of 5.8% and growth rates of 3.0%.
As of Jan 17, 2025, Pfizer Inc.'s Weighted Average Cost of Capital (WACC) is approximately 5.8%.
As of Jan 17, 2025, Pfizer Inc.'s Enterprise Value (EV) is approximately $769.9B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.